Oncolytic polio/rhinovirus recombinant (pvsripo) in recurrent glioblastoma (gbm): first phase I clinical trial evaluating the intratumoral administration.
Publication
, Journal Article
Desjardins, A; Sampson, JH; Peters, KB; Ranjan, T; Vlahovic, G; Threatt, S; Herndon, JE; Boulton, S; Lally-Goss, D; McSherry, F; Friedman, AH ...
Published in: Neuro Oncol
July 2014
PVSRIPO is the live attenuated, oral (SABIN) serotype 1 poliovirus vaccine containing a heterologous internal ribosomal entry site stemming from human rhinovirus type 2. PVSRIPO recognizes nectin-like molecule-5, an oncofetal cell adhesion molecule and tumor antigen widely expressed ectopically in malignancy. Within, we report on the ongoing phase I study evaluating the intratumoral convection-enhanced delivery (CED) of PVSRIPO.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Neuro Oncol
DOI
EISSN
1523-5866
Publication Date
July 2014
Volume
16 Suppl 3
Start / End Page
iii43
Location
England
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Desjardins, A., Sampson, J. H., Peters, K. B., Ranjan, T., Vlahovic, G., Threatt, S., … Gromeier, M. (2014). Oncolytic polio/rhinovirus recombinant (pvsripo) in recurrent glioblastoma (gbm): first phase I clinical trial evaluating the intratumoral administration. Neuro Oncol, 16 Suppl 3, iii43. https://doi.org/10.1093/neuonc/nou209.5
Desjardins, A., J. H. Sampson, K. B. Peters, T. Ranjan, G. Vlahovic, S. Threatt, J. E. Herndon, et al. “Oncolytic polio/rhinovirus recombinant (pvsripo) in recurrent glioblastoma (gbm): first phase I clinical trial evaluating the intratumoral administration.” Neuro Oncol 16 Suppl 3 (July 2014): iii43. https://doi.org/10.1093/neuonc/nou209.5.
Desjardins A, Sampson JH, Peters KB, Ranjan T, Vlahovic G, Threatt S, et al. Oncolytic polio/rhinovirus recombinant (pvsripo) in recurrent glioblastoma (gbm): first phase I clinical trial evaluating the intratumoral administration. Neuro Oncol. 2014 Jul;16 Suppl 3:iii43.
Desjardins, A., et al. “Oncolytic polio/rhinovirus recombinant (pvsripo) in recurrent glioblastoma (gbm): first phase I clinical trial evaluating the intratumoral administration.” Neuro Oncol, vol. 16 Suppl 3, July 2014, p. iii43. Pubmed, doi:10.1093/neuonc/nou209.5.
Desjardins A, Sampson JH, Peters KB, Ranjan T, Vlahovic G, Threatt S, Herndon JE, Boulton S, Lally-Goss D, McSherry F, Friedman AH, Friedman HS, Bigner DD, Gromeier M. Oncolytic polio/rhinovirus recombinant (pvsripo) in recurrent glioblastoma (gbm): first phase I clinical trial evaluating the intratumoral administration. Neuro Oncol. 2014 Jul;16 Suppl 3:iii43.
Published In
Neuro Oncol
DOI
EISSN
1523-5866
Publication Date
July 2014
Volume
16 Suppl 3
Start / End Page
iii43
Location
England
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences